- Home
- HCM
as 05-20-2024 12:32pm EST
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
| Founded: | N/A | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 3.4B | IPO Year: | N/A |
| Target Price: | $29.70 | AVG Volume (30 days): | 145.3K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.68 - $21.92 | Next Earning Date: | 02-28-2024 |
| Revenue: | $837,999,000 | Revenue Growth: | 135.31% |
| Revenue Growth (this year): | -13.66% | Revenue Growth (next year): | 19.84% |
Share on Social Networks:
Latest HUTCHMED (China) Limited News
HCM Breaking Stock News: Dive into HCM Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
GlobeNewswire
4 days ago
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
GlobeNewswire
7 days ago
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
GlobeNewswire
7 days ago
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
GlobeNewswire
12 days ago
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
GlobeNewswire
24 days ago
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
Simply Wall St.
a month ago
HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
GlobeNewswire
a month ago